KEGG   DRUG: Ropeginterferon alfa-2b
Entry
D11027                      Drug                                   

Name
Ropeginterferon alfa-2b (INN);
Ropeginterferon alfa-2b (genetical recombination) (JAN)
Sequence
PCDLPQTHSL GSRRTLMLLA QMRRISLFSC LKDRHDFGFP QEEFGNQFQK AETIPVLHEM
IQQIFNLFST KDSSAAWDET LLDKFYTELY QQLNDLEACV IQGVGVTETP LMKEDSILAV
RKYFQRITLY LKEKKYSPCA WEVVRAEIMR SFSLSTNLQE SLRSKE
(Disulfide bridge: 2-99, 30-139)
  Type
Peptide
Remark
ATC code: L03AB15
Efficacy
Antineoplastic, Antiviral
Target
IFNAR1 [HSA:3454] [KO:K05130]
IFNAR2 [HSA:3455] [KO:K05131]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04620  Toll-like receptor signaling pathway
hsa04630  JAK-STAT signaling pathway
hsa04650  Natural killer cell mediated cytotoxicity
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L03 IMMUNOSTIMULANTS
   L03A IMMUNOSTIMULANTS
    L03AB Interferons
     L03AB15 Ropeginterferon alfa-2b
      D11027  Ropeginterferon alfa-2b (INN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Interferon receptors
    IFNAR1
     D11027  Ropeginterferon alfa-2b (INN)
    IFNAR2
     D11027  Ropeginterferon alfa-2b (INN)
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11027
Other DBs
CAS: 1335098-50-4
PubChem: 350078346
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system